Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP853696.RAVGayZNeDBo3y8vdbcIDKYCrxnREzbjZ73pdZFDadR8A130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP853696.RAVGayZNeDBo3y8vdbcIDKYCrxnREzbjZ73pdZFDadR8A130_provenance.
• NP345600.RArpIXbHvXlami1F5wnwa-r32Q56wDOTYslBm7GYAZKCg130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP345600.RArpIXbHvXlami1F5wnwa-r32Q56wDOTYslBm7GYAZKCg130_provenance.
• NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP163094.RAbCDHT0e7-PEcLTSLk5Z6iSCQ9V6K5eQHvn7rznVxUUg130_provenance.
• assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP369445.RAZcDNHonAeiV86uMxVDktPc660kqArxxOlnZC5N-s0BE130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP369445.RAZcDNHonAeiV86uMxVDktPc660kqArxxOlnZC5N-s0BE130_provenance.
• NP379509.RAQyaE4qlGrjnt2NUC8v0jUaEDztc0mDHABQoZUZ560B0130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379509.RAQyaE4qlGrjnt2NUC8v0jUaEDztc0mDHABQoZUZ560B0130_provenance.
• NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_provenance.
• NP773981.RAT8WsU1Gqxf-uu01nfgFeVUozKdubh-9lUIAh0BzHu90130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773981.RAT8WsU1Gqxf-uu01nfgFeVUozKdubh-9lUIAh0BzHu90130_provenance.
• NP773983.RATIvHp8XlfJ1apolaCpc2dBK1aS9G4XwCkbpULRkzPpI130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773983.RATIvHp8XlfJ1apolaCpc2dBK1aS9G4XwCkbpULRkzPpI130_provenance.
• NP680480.RAry_MAr2J8DJ-HJhosF3ZVSth7dqsH71OZAN3idMTUFg130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680480.RAry_MAr2J8DJ-HJhosF3ZVSth7dqsH71OZAN3idMTUFg130_provenance.
• NP773977.RAmPusuJS1dDCZFZ6wHz5VeArMoKINrTIwxHsUTdtkLv8130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773977.RAmPusuJS1dDCZFZ6wHz5VeArMoKINrTIwxHsUTdtkLv8130_provenance.
• NP773978.RAnp4ovW2DePo6cPFi0rd9gpMFGt3I2zkikVfpcxR-VLo130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773978.RAnp4ovW2DePo6cPFi0rd9gpMFGt3I2zkikVfpcxR-VLo130_provenance.
• NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_provenance.
• NP379301.RAPofo86y04T89tNpGz4jVy5vWwU0N0mSkbc3LUwjnxHw130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379301.RAPofo86y04T89tNpGz4jVy5vWwU0N0mSkbc3LUwjnxHw130_provenance.
• NP680531.RAMvTV1ibMfOleRsTOxEK8zTf7YfZrMC4asR6aZBj6Vz0130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680531.RAMvTV1ibMfOleRsTOxEK8zTf7YfZrMC4asR6aZBj6Vz0130_provenance.
• NP773974.RAKpM0Xh02n11omFT8HzEELE_tSIXIGkVGVT9mb7mIQBQ130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773974.RAKpM0Xh02n11omFT8HzEELE_tSIXIGkVGVT9mb7mIQBQ130_provenance.
• NP773975.RAwj42mmZSSmAmgKEiglvZwikgG-IEE5G3CYNoVWQQlus130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773975.RAwj42mmZSSmAmgKEiglvZwikgG-IEE5G3CYNoVWQQlus130_provenance.
• NP773980.RA97eloM3ORloKe9L_Gbz1tqlrqfIy_HuEld7N7G89gRc130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773980.RA97eloM3ORloKe9L_Gbz1tqlrqfIy_HuEld7N7G89gRc130_provenance.
• NP773982.RA_Y0M2gy8fCh7ly373pv6WRRdrWPqouAhFvwMAYIGxRI130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773982.RA_Y0M2gy8fCh7ly373pv6WRRdrWPqouAhFvwMAYIGxRI130_provenance.